Vir enrols first subject in Phase III programme to assess CHD therapy
The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory ...
High Growth Tech in Europe Featuring Three Promising Stocks
Amidst a backdrop of uncertainty surrounding U.S. trade policy and economic fluctuations, the European market has been experiencing mixed results, with the pan-European STOXX Europe 600 Index ending ...